Small Molecule MYC Inhibitor Conjugated to Integrin-Targeted Nanoparticles Extends Survival in a Mouse Model of Disseminated Multiple Myeloma

VLA-4-targeted nanoparticles incorporating the MI1-PD prodrug significantly increased survival in a mouse model of multiple myeloma, with the smaller particles providing a greater benefit.

• The MI1-PD prodrug decreased cell growth and triggered cell death in multiple myeloma cell lines.
• Binding and effectiveness of nanoparticles were closely linked to the level of integrin expression on multiple myeloma cells.
• In a metastatic mouse model, the targeted nanoparticles improved survival to 52 days with the smaller size compared to 29 days for the control.
• Larger nanoparticles also showed a survival benefit, but less than their smaller counterparts.
• Neither MI1 nor MI1-PD offered a survival advantage when given systemically as standalone treatments.

AI simplified